Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

GHRSBullishIndustry Newsnews

High materiality7/10

GH Research rises on TRD data, FDA hold lift, and Phase 3 progress

Jul 16, 2026, 12:57 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive trial data, IND hold lift, and Phase 3 progress create near-term upside risk for GHRS; relative performance vs peers like CMPS supports a bullish read.

AI summary

What happened, with direct paths to the underlying reporting

GHRS received positive catalysts from robust TRD data for GH001, a cleared path toward Phase 3 after the FDA IND hold was lifted. UK Phase 1 pharmacology results informed dosing for the pivotal program, while BPL-003's shorter duration may offer a competitive edge. The stock moved higher on the news, underscoring near-term upside if Phase 3 execution remains on track.

GH001 Phase 2b TRD data published in JAMA Psychiatry (March 2026). Day 8 remission 53.9%-63.6% across subgroups.
May 2026: UK Phase 1 pharmacology trial completed enrolment for GH001 delivery device.
FDA lifted GH001 IND hold in January; hold originally placed September 2023.
Bloomberg notes BPL-003 offers 1-2 hour psychedelic effects, shorter than rivals.
GHRS shares rose 11.40% to $29.99 after Bloomberg/Benzinga market news.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

GH Research rises on TRD data, FDA hold lift, and Phase 3 progress

GH Research Misses Q1 Earnings Estimations but Progresses in Trials

FDA Lifts Hold On GH Research's Depression Drug Trial After Two Years

Depression-Focused GH Research Shares Could See Significant Upside: Analyst